The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 10, 2011
Filed:
Dec. 13, 2005
Marcello Allegretti, L'Aquila, IT;
Riccardo Bertini, L'Aquila, IT;
Andrea Beccari, L'Aquila, IT;
Alessio Moriconi, L'Aquila, IT;
Andrea Aramini, L'Aquila, IT;
Cinzia Bizzarri, L'Aquila, IT;
Francesco Colotta, L'Aquila, IT;
Marcello Allegretti, L'Aquila, IT;
Riccardo Bertini, L'Aquila, IT;
Andrea Beccari, L'Aquila, IT;
Alessio Moriconi, L'Aquila, IT;
Andrea Aramini, L'Aquila, IT;
Cinzia Bizzarri, L'Aquila, IT;
Francesco Colotta, L'Aquila, IT;
DompePHA.R.MA S.p.A., L'Aquila, IT;
Abstract
The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.